Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 22

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 3
Chunk 22
---
uption or delays in the operations of the FDA, the EMA or other foreign regulatory agencies, which may impact approval timelines;
 •interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in our supply chain or distribution vendors’ ability to ship product candidates; and
 •limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families, the desire of employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit disruptions.
 These and other factors could further adversely impact our ability to conduct clinical trials and our business generally, and could have a material adverse impact on our operations and financial condition and results.
 In addition, the trading prices for our ADSs and for the securities of other biopharmaceutical companies may be highly volatile during certain periods as a result of a pandemic. As a result, we may face difficulties raising capital through sales of our ADSs or such sales may be on unfavorable terms. The extent to which a pandemic may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the emergence, severity and spread of new variants of a disease, the duration of a pandemic and any

outbreak of future variants, the potential imposition of travel restrictions and actions to contain a pandemic and any future outbreaks, such as social distancing and quarantines or lock-downs in the United Kingdom, the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United Kingdom, the United States and other countries to contain and treat a disease.
 The ongoing conflicts in Ukraine and the Middle East could adversely impact our business, in particular with respect to enrollment and data collection in any clinical trials of our product candidates that may be conducted in Ukraine, Russia, Belarus or the Middle East.
 The ongoing military and geopolitical conflicts in Ukraine and the Middle East could disrupt our clinical trials that may be conducted in these regions and increase our costs in these regions. Although the length and impacts of any military action or geopolitical conflicts are highly unpredictable, clinical trial sites that may be established in Ukraine, Russia and Belarus and neighboring countries, as well as in the Middle East could suspend or terminate their participation in trials, and patients and physicians could be forced to evacuate or voluntarily choose to relocate far from clinical trial sites, making them